sj-docx-1-tab-10.1177_1759720X211067639 ��� Supplemental material for Based on minimal clinically important difference values, a moderate dose of tanezumab may be a better option for treating hip or knee osteoarthritis: a meta-analysis of randomized controlled trials

Supplemental material, sj-docx-1-tab-10.1177_1759720X211067639 for Based on minimal clinically important difference values, a moderate dose of tanezumab may be a better option for treating hip or knee osteoarthritis: a meta-analysis of randomized controlled trials by Di Zhao, Ming-hui Luo, Jian-ke Pan, Ling-feng Zeng, Gui-hong Liang, Yan-hong Han, Jun Liu and Wei-yi Yang in Therapeutic Advances in Musculoskeletal Disease